Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Get Thin MD vs LVNG RX

Get Thin MD
Graded #179

Higher grade

vs+4.200000000000003
LVNG RX
Graded #268

Lower grade

The verdict

Get Thin MD takes it — 66.7/100 to 62.5/100.

Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLVNG RX +14
50
64
Dose & formulationGet Thin MD +13
77
64
Clinical oversightGet Thin MD +34
90
56
Labs & monitoringLVNG RX +7
55
62
FulfillmentGet Thin MD +22
91
69
Contract termsLVNG RX +41
20
61
Get Thin MD · left barLVNG RX · right bar

The numbers

MetricGet Thin MDLVNG RX
WeighScore66.7/10062.5/100
GradeCC
Scorecard rank#179#268
Semaglutide$199/mo (compounded)$149/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$249/mo (microdose tier, starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Get Thin MD

Graded #179 · C

Strengths

  • 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
  • Price-lock promise — same price every dose, no hidden fees
  • Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
  • Nationwide availability with async evaluation — no in-person visit
  • Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols

Where it loses points

  • Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
  • Pharmacy partners not named — no way to verify the compounding source or batch testing
  • Claims nationwide coverage but publishes no state list — confirm at intake
  • Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
  • Wide wellness funnel may steer you toward non-weight-loss protocols
LVNG RX

Graded #268 · C

Strengths

  • One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
  • States you are charged nothing if a provider does not approve you for treatment
  • Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
  • Semaglutide from $149/mo is competitive against the wider compounded market
  • Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide

Where it loses points

  • Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
  • Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
  • Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
  • The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
  • No compounding pharmacy, medical group or individual clinician is named anywhere on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard